BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). (Q50420977)
Jump to navigation
Jump to search
scientific article published on 21 September 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). |
scientific article published on 21 September 2017 |
Statements
1 reference
BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). (English)
1 reference
Audrey Benyamine
Céline Loncle
Etienne Foucher
Juan-Luis Blazquez
Céline Castanier
Anne-Sophie Chrétien
Véronique Secq
Meritxell Gironella
Elena Vila-Navarro
Giuseppe Montalto
Jean-Charles Dagorn
21 September 2017
1 reference
1 reference
1 reference
1 reference
1 reference